NCT03690336

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 10 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect data on adverse events from third party registries that include information about adverse events from patients with haemophilia B treated with nonacog beta pegol. The third party registries include PedNet Haemophilia Registry (PedNet) and the European Haemophilia Safety Surveillance System (EUHASS). Data from national and international registries in countries where nonacog beta pegol has been approved and marketed could be included in the data collection.

Conditions

• Haemophilia B

Interventions

Type	Name	Description
DRUG	Nonacog beta pegol	Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.

Timeline

• Start date: 2018-10-01
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2018-10-01
• Last updated: 2025-06-02

Locations

2 sites across 2 countries: Netherlands, United Kingdom